Existing NXTC shareholders face massive dilution. The stock will likely trade down toward the implied stub value of the combined company. Monitor the proxy statement and stockholder vote for approval. The PIPE investors' entry price and the CVR potential from legacy assets are key variables. Consider the risk of the deal failing if conditions (e.g., Nasdaq listing, PIPE close) are not met.
Price Chart
Executive Summary
NextCure (NXTC) entered into a definitive agreement to merge with Avere Therapeutics in a reverse merger, where Avere shareholders will receive a majority stake in the combined entity. The deal values Avere at $250M equity value and values NextCure at $11M, implying existing NXTC shareholders will retain roughly 2.7% of the combined company. Concurrently, the company secured a $150M minimum PIPE to fund the combined entity and announced a restructuring to wind down its legacy business.
Key Financial Metrics
Key Facts
- NextCure (Parent) valued at $11M in the merger; Avere valued at $250M equity value.
- Existing NXTC shareholders will own approximately 2.7% of the combined company based on the valuation split.
- $150M minimum PIPE (Securities Purchase Agreement) committed by investors concurrent with the closing.
- Merger structured as a reverse triangular merger: First Merger Sub merges into Avere, then Avere merges into Second Merger Sub.
- Contingent Value Rights (CVRs) issued to NXTC shareholders for proceeds from legacy asset wind-down.
- Restructuring (Item 2.05) for exit/disposal of the Parent Legacy Business.
- Change in control (Item 5.01) with Avere designating the new board and officers.
- Termination fee: Parent pays $330k; Company pays $2M if conditions met.
Financial Impact
Extreme dilution: NXTC shareholders' ownership drops from 100% to ~2.7% of the combined entity. A $150M PIPE will be injected at a per-share price derived from the Avere valuation. The merged entity will operate as Avere Therapeutics, Inc. with NextCure's legacy assets being wound down.
Risk Factors
- Massive dilution to existing NXTC shareholders (~2.7% pro forma ownership).
- Deal failure risk: conditions include Nasdaq listing, stockholder approval, regulatory approvals, and PIPE closing.
- Legacy business wind-down costs may reduce CVR proceeds.
- Combined entity may face integration and operational risks.
- CVR value is contingent and uncertain; could be zero.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-083326 |
| Document: tm2620428d1_ex10-3.htm | 0001104659-26-083326 |
| Document: tm2620428d1_ex10-6.htm | 0001104659-26-083326 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.72 (+5.06%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.72 (+15.08%) |
Aug 4, 2026 12w ago | 425 | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.72 (+13.62%) |
Jul 14, 2026 15w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.72 (−13.15%) |
Jul 14, 2026 15w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.72 (+13.15%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.72 (+69.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers